Momentum in the space has increased in recent years driven by encouraging clinical data and strong recent launches targeting neuroendocrine tumors and prostate cancer.
Radiopharmaceuticals, or radioligand therapies, are another targeted form of cancer treatment that deliver radiation to specifically targeted cancer cells, with minimal effect on surrounding healthy tissue.  Momentum in the space has increased in recent years driven by encouraging clinical data and strong recent launches targeting neuroendocrine tumors and prostate cancer. In our view, this innovation, despite recent progress, is still in the early stages and the modality will continue to build on the precision oncology and ADC themes.